Modulating the immune system to delay the clinical onset of type 1 diabetes.

Sugahara, Mai; Tanaka, Tetsuhiro; Nangaku, Masaomi

Sugahara, Mai; Tanaka, Tetsuhiro; Nangaku, Masaomi.

Afiliação

Sugahara M; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Tanaka T; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Nangaku M; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. Electronic address: mnangaku-tky@umin.ac.jp.

Kidney Int ; 97(2): 248-250, 2020 02.

Article em En | MEDLINE | ID: mdl-31980070

Assuntos

Diabetes Mellitus Tipo 1; Anticorpos Monoclonais Humanizados; Humanos; Sistema Imunitário

Palavras-chave

C-peptide; teplizumab; type 1 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google